Establishment Labs Reports Strong Q4 2025 Earnings and Optimistic 2026 Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 27 2026
0mins
Should l Buy ESTA?
Source: seekingalpha
Establishment Labs Holdings Inc. shares rose 4.44% as the company reached a 52-week high.
The strong performance was driven by the release of their Q4 2025 earnings report, which highlighted a 45.2% year-over-year revenue growth to $64.6 million, with U.S. Motiva sales contributing significantly. The company also reported a gross margin improvement to 70.5% and provided an optimistic revenue guidance for 2026, projecting between $264 million and $266 million, indicating sustained growth potential.
This positive financial performance reflects the company's effective cost management and operational efficiency, alongside a robust market demand for their products, positioning Establishment Labs for continued success in the upcoming year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ESTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ESTA
Wall Street analysts forecast ESTA stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 70.240
Low
75.00
Averages
82.88
High
90.00
Current: 70.240
Low
75.00
Averages
82.88
High
90.00
About ESTA
Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Establishment Labs Secures $300M Loan for Refinancing and Growth
- Financing Structure Optimization: Establishment Labs has entered into a $300 million senior secured term loan with Oaktree Capital Management, split into $265 million for refinancing and $35 million for growth capital, significantly enhancing the company's financial flexibility.
- Debt Maturity Extension: The loan extends the maturity to 2031 and features a fixed interest rate with potential reductions linked to leverage targets, further strengthening the company's financial stability and future expansion capabilities.
- Cash Flow Expectations: This loan agreement is expected to support positive free cash flow in the second half of 2026, indicating the company's financial health and growth potential in the future.
- Revenue Growth Target: Establishment Labs aims for at least 25% revenue growth in 2026 while expanding its minimally invasive platforms, reflecting the company's proactive strategy in its transition towards profitable scale.
See More
Establishment Labs Insider Sells 37,500 Shares Amid Strong Growth
- Transaction Overview: On April 14, 2026, Establishment Labs Director Juan Jose Chacon Quiros sold 37,500 shares through an indirect market transaction valued at $2.45 million, indicating routine liquidity management under a pre-arranged Rule 10b5-1 plan.
- Ownership Changes: Post-transaction, Chacon Quiros retains 45,193 shares directly and 1,182,504 shares indirectly, reflecting a 3% reduction in indirect holdings while direct ownership remains unchanged, suggesting continued confidence in the company.
- Market Performance: The shares were sold at $65.23 each, with Establishment Labs experiencing a 128.09% price increase over the past year, highlighting the company's robust growth potential in the medical device sector.
- Financial Health: The company reported a 45% year-over-year revenue increase in Q4, reaching $64.6 million, with total annual revenue of $211.1 million, and management projects over 25% growth in 2026, indicating sustained market demand and improving profitability.
See More
Director of Establishment Labs (ESTA.US) Proposes Sale of $20.67 Million in Common Stocks via Form 144
Stock Sale Announcement: Establishment Labs' Director Juan Jose Chacon Quiros plans to sell 330,000 shares of its common stock.
Market Value: The total market value of the shares being sold is approximately $20.67 million.
See More
Rice Hall James Increases Stake in QuidelOrtho
- Share Increase: Rice Hall James & Associates acquired 574,877 shares of QuidelOrtho in Q4 2026, reflecting confidence in the company's future prospects despite a 43.4% decline in stock price over the past year.
- Investment Value: This acquisition raised QuidelOrtho's stake to 1.3% of the fund's 13F reportable assets, indicating recognition of its potential value, which may attract further investor interest.
- Market Performance: As of February 13, 2026, QuidelOrtho's market capitalization stood at $1.6 billion with a current price of $23.58, trailing the S&P 500 by 55.2 percentage points, highlighting competitive pressures in the market.
- Strategic Adjustments: QuidelOrtho is undergoing strategic adjustments, including strengthening its product pipeline and improving spending returns, with analysts expecting these efforts to yield modest revenue and operating profit growth in the coming years.
See More
Rice Hall James Increases Stake in QuidelOrtho
- Increased Holdings: Rice Hall James purchased 574,877 shares of QuidelOrtho in Q4, raising its total stake to 833,791 shares valued at $23.8 million, reflecting a positive outlook on the company's future prospects.
- Investment Value Growth: The position's value increased by $16.2 million at quarter-end, indicating a rise in stock price and additional share purchases, suggesting the fund's optimistic view on QuidelOrtho's potential value.
- Industry Position: As a leader in in vitro diagnostics, QuidelOrtho has struggled with consistent revenue growth and profitability in recent years, but its strategic adjustments and strengthened product pipeline may improve financial performance, attracting value investors.
- Market Expectations: Analysts expect QuidelOrtho to achieve modest revenue and operating profit growth in the coming years, although the Motley Fool analyst team did not include it in their list of top investment stocks, indicating a divergence in market perceptions of its potential.
See More
Rice Hall James Increases Stake in Stride by 122,430 Shares
- Share Increase: Rice Hall James & Associates, LLC increased its stake in Stride by 122,430 shares in Q4 2026, bringing its ownership to 1.5%, indicating confidence in Stride's future growth potential.
- Market Value Fluctuation: Despite the increase, Stride's quarter-end market value fell by $17.7 million, reflecting the impact of stock price movements and additional shares, suggesting market concerns about its short-term performance.
- Earnings Outlook: During Stride's Q4 earnings call, management reaffirmed full-year revenue guidance while raising adjusted operating income expectations, indicating that the market's negative reaction may have been overstated, presenting a potential undervaluation opportunity.
- Market Performance: Stride's stock price has dropped 39.5% over the past year and underperformed the S&P 500 by 51.2 percentage points, highlighting challenges in the education market but also providing potential buying opportunities for investors.
See More
Establishment Labs Secures $300M Loan for Refinancing and Growth
- Financing Structure Optimization: Establishment Labs has entered into a $300 million senior secured term loan with Oaktree Capital Management, split into $265 million for refinancing and $35 million for growth capital, significantly enhancing the company's financial flexibility.
- Debt Maturity Extension: The loan extends the maturity to 2031 and features a fixed interest rate with potential reductions linked to leverage targets, further strengthening the company's financial stability and future expansion capabilities.
- Cash Flow Expectations: This loan agreement is expected to support positive free cash flow in the second half of 2026, indicating the company's financial health and growth potential in the future.
- Revenue Growth Target: Establishment Labs aims for at least 25% revenue growth in 2026 while expanding its minimally invasive platforms, reflecting the company's proactive strategy in its transition towards profitable scale.
See More
Establishment Labs Insider Sells 37,500 Shares Amid Strong Growth
- Transaction Overview: On April 14, 2026, Establishment Labs Director Juan Jose Chacon Quiros sold 37,500 shares through an indirect market transaction valued at $2.45 million, indicating routine liquidity management under a pre-arranged Rule 10b5-1 plan.
- Ownership Changes: Post-transaction, Chacon Quiros retains 45,193 shares directly and 1,182,504 shares indirectly, reflecting a 3% reduction in indirect holdings while direct ownership remains unchanged, suggesting continued confidence in the company.
- Market Performance: The shares were sold at $65.23 each, with Establishment Labs experiencing a 128.09% price increase over the past year, highlighting the company's robust growth potential in the medical device sector.
- Financial Health: The company reported a 45% year-over-year revenue increase in Q4, reaching $64.6 million, with total annual revenue of $211.1 million, and management projects over 25% growth in 2026, indicating sustained market demand and improving profitability.
See More
Director of Establishment Labs (ESTA.US) Proposes Sale of $20.67 Million in Common Stocks via Form 144
Stock Sale Announcement: Establishment Labs' Director Juan Jose Chacon Quiros plans to sell 330,000 shares of its common stock.
Market Value: The total market value of the shares being sold is approximately $20.67 million.
See More
Rice Hall James Increases Stake in QuidelOrtho
- Share Increase: Rice Hall James & Associates acquired 574,877 shares of QuidelOrtho in Q4 2026, reflecting confidence in the company's future prospects despite a 43.4% decline in stock price over the past year.
- Investment Value: This acquisition raised QuidelOrtho's stake to 1.3% of the fund's 13F reportable assets, indicating recognition of its potential value, which may attract further investor interest.
- Market Performance: As of February 13, 2026, QuidelOrtho's market capitalization stood at $1.6 billion with a current price of $23.58, trailing the S&P 500 by 55.2 percentage points, highlighting competitive pressures in the market.
- Strategic Adjustments: QuidelOrtho is undergoing strategic adjustments, including strengthening its product pipeline and improving spending returns, with analysts expecting these efforts to yield modest revenue and operating profit growth in the coming years.
See More
Rice Hall James Increases Stake in QuidelOrtho
- Increased Holdings: Rice Hall James purchased 574,877 shares of QuidelOrtho in Q4, raising its total stake to 833,791 shares valued at $23.8 million, reflecting a positive outlook on the company's future prospects.
- Investment Value Growth: The position's value increased by $16.2 million at quarter-end, indicating a rise in stock price and additional share purchases, suggesting the fund's optimistic view on QuidelOrtho's potential value.
- Industry Position: As a leader in in vitro diagnostics, QuidelOrtho has struggled with consistent revenue growth and profitability in recent years, but its strategic adjustments and strengthened product pipeline may improve financial performance, attracting value investors.
- Market Expectations: Analysts expect QuidelOrtho to achieve modest revenue and operating profit growth in the coming years, although the Motley Fool analyst team did not include it in their list of top investment stocks, indicating a divergence in market perceptions of its potential.
See More
Rice Hall James Increases Stake in Stride by 122,430 Shares
- Share Increase: Rice Hall James & Associates, LLC increased its stake in Stride by 122,430 shares in Q4 2026, bringing its ownership to 1.5%, indicating confidence in Stride's future growth potential.
- Market Value Fluctuation: Despite the increase, Stride's quarter-end market value fell by $17.7 million, reflecting the impact of stock price movements and additional shares, suggesting market concerns about its short-term performance.
- Earnings Outlook: During Stride's Q4 earnings call, management reaffirmed full-year revenue guidance while raising adjusted operating income expectations, indicating that the market's negative reaction may have been overstated, presenting a potential undervaluation opportunity.
- Market Performance: Stride's stock price has dropped 39.5% over the past year and underperformed the S&P 500 by 51.2 percentage points, highlighting challenges in the education market but also providing potential buying opportunities for investors.
See More
